ERBB2 and adenocarcinoma: Suzuki et al. published an HER2 positivity of 2.6% on a sample of 1055 adenocarcinomas [6], while a slightly more frequent HER2 overexpression was reported by Kobyakov et al. –6.1% [24] and Kim et al. –7.8% [25].